hVIVO (LON:HVO) Issues Earnings Results

hVIVO (LON:HVO) announced its quarterly earnings data on Tuesday. The company reported GBX (0.82) earnings per share for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.

hVIVO Stock Performance

Shares of hVIVO stock traded down GBX 0.22 during trading on Wednesday, hitting GBX 5.88. 1,590,903 shares of the company’s stock traded hands, compared to its average volume of 2,547,441. hVIVO has a 1 year low of GBX 4.30 and a 1 year high of GBX 11. The business has a 50-day simple moving average of GBX 6.81 and a 200-day simple moving average of GBX 7.41. The stock has a market capitalization of £40.48 million, a P/E ratio of -6.76 and a beta of 1.69. The company has a debt-to-equity ratio of 38.75, a current ratio of 1.63 and a quick ratio of 1.16.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.